Why this conversation matters
For people with estrogen- and progesterone-receptor–positive breast cancer, endocrine therapy is one of the most effective tools we have to reduce recurrence risk. At the same time, it can be physically and emotionally taxing, especially over many years. Patients have been asking the same core questions for decades:
Is it ever safe to pause endocrine therapy?
How long is “long enough”?
Does everyone benefit from extended suppression?
Where does hormone therapy, including bioidentical hormone therapy, fit into survivorship?
Recent research has not erased uncertainty, but it has meaningfully changed how we approach these questions.
The POSITIVE study and what it changed
The POSITIVE study directly addressed a question many young survivors carry quietly:
Is it safe to temporarily stop endocrine therapy to attempt pregnancy?
In POSITIVE, premenopausal women age 42 and under who had completed about 18 to 30 months of endocrine therapy were allowed to pause treatment, complete a washout period, and remain off therapy for up to 2 years while attempting pregnancy and breastfeeding.
With nearly six years of follow-up, a planned interruption did not appear to increase breast cancer events compared with expected outcomes from similar patients in SOFT/TEXT.
This was genuinely reassuring. It does not mean endocrine therapy is unnecessary, but it shows that timing and duration can sometimes be flexible, without clearly compromising short-term outcomes.
We still need longer follow-up and more data for higher-risk patients and for modern-era treatments, including CDK4/6 inhibitors. Even so, POSITIVE has already changed survivorship counseling.
The next question POSITIVE raises
If a planned interruption can be safe for some patients, it naturally leads to a broader question:
Does everyone need long-term, uninterrupted endocrine suppression, and for how long?
Endocrine therapy remains foundational in ER+/PR+ breast cancer. The shift is not away from treatment (for now), but toward individualization. Read on…
What we know about extended endocrine therapy
Several high-quality trials help shape the “how long is long enough?” conversation.
Extending therapy to 10 years
MA.17R(extended letrozole after prior endocrine therapy): improved disease-free survival, but no clear overall survival advantage at the time of reporting, with more bone-related toxicity (including fractures and osteoporosis).
NSABP B-42 (extended letrozole): long-term follow-up shows a disease-free survival benefit and fewer distant recurrences, but no overall survival improvement, reinforcing the need to individualize.
When longer is not better
ABCSG-16 / SALSA: comparing 2 versus 5 years of extended anastrozole found no advantage to longer duration, and fracture risk was higher with longer therapy.
IDEAL trial: comparing 2.5 versus 5 years of extended letrozole did not show superiority of the longer duration for key outcomes.
The real-world problem
Even when trials show benefit, many patients stop therapy early due to side effects such as joint pain, sleep disruption, sexual dysfunction, mood changes, cognitive symptoms, and bone loss.
A medication can only help if someone can tolerate staying on it.
What else are we missing?
POSITIVE also reminds us of something biologically interesting and relevant.
During pregnancy, estrogen and progesterone rise to levels far beyond anything seen outside pregnancy, yet pregnancy after hormone-receptor–positive breast cancer can be safe in certain patients. This raises a question we do not yet have good answers to:
How might physiologic-dose bioidentical hormone therapy affect long-term outcomes and quality of life in some survivors?
What we know about hormone therapy after breast cancer
Randomized recurrence data
HABITS trial: higher new breast cancer events overall (including both recurrence and new primary cancers) with systemic hormone therapy, largely estradiol plus a synthetic progestogen (norethisterone). This led to early trial termination.
Stockholm trial: designed to minimize progestogen exposure. At long-term follow-up, overall new breast cancer events were not clearly increased, but contralateral (new opposite-breast) cancers were higher. The Stockholm regimen was estradiol-focused with minimal, intermittent synthetic progestogen.
LIBERATE trial: increased recurrence with tibolone. Tibolone is not bioidentical; it has estrogenic, progestogenic, and androgenic activity and remains an important cautionary signal in the “systemic hormones after breast cancer” literature.
Observational data
Cold et al., JNCI 2022:
Systemic menopausal hormone therapy was not associated with increased recurrence, but hormone exposure consisted mainly of vaginal estrogen and, in a very small subset, mixed systemic regimens using oral or transdermal estradiol with predominantly synthetic progestins (norethisterone or medroxyprogesterone acetate), with micronized progesterone rarely used. Vaginal estrogen was generally reassuring, except for a higher recurrence signal when started during aromatase inhibitor therapy.
What is missing
There are no clean recurrence-outcome trials that isolate FDA-approved bioidentical systemic regimens such as transdermal estradiol plus oral micronized progesterone in breast cancer survivors.
Primary-prevention data suggesting lower breast cancer incidence with micronized progesterone cannot be substituted for recurrence data.
What about other cancers?
For non-breast cancers, the evidence is often more permissive.
Ovarian cancer: randomized data suggest no harm and possible survival benefit with estrogen therapy.
Early-stage endometrial cancer: generally no increased recurrence in stage I to II disease.
Cervical cancer: menopausal hormone therapy is not associated with worse outcomes in appropriate survivors.
“Is there anything natural that works like endocrine therapy?”
In short, no.
Nothing suppresses estrogen as powerfully or consistently as tamoxifen, aromatase inhibitors, or ovarian suppression.
Some compounds can modulate estrogen metabolism, but this is not the same as estrogen suppression.
DIM may shift estrogen metabolite patterns but does not reliably lower serum estradiol.
Sulforaphane supports detoxification pathways, but evidence for large, consistent estradiol reduction in humans is limited.
NAC supports glutathione and redox balance, which can matter for how reactive estrogen metabolites are cleared.
A helpful nuance: not all estrogen metabolites act the same
Estradiol can be metabolized into pathways that include 2-hydroxy, 4-hydroxy, and 16α-hydroxy metabolites, and these metabolites differ in biologic activity:
2-hydroxy estrogens are generally considered less estrogenic and often described as less proliferative.
16α-hydroxy estrogens are more strongly estrogenic and associated with more proliferative signaling.
4-hydroxy estrogens can form reactive quinones that increase oxidative stress and can be more genotoxic if not adequately cleared.
This is why estrogen metabolism matters, not just estrogen levels. When detoxification pathways are functioning well, reactive metabolites are conjugated and eliminated. When these pathways are overwhelmed, more reactive metabolites can persist longer in tissues, potentially increasing biologic risk even without high circulating estradiol.
The take-home
Endocrine therapy remains a powerful tool, but the field is clearly moving toward precision rather than one-size-fits-all use. The future of care is not less treatment, but better matched treatment.
POSITIVE reframes what is possible in survivorship, supporting that in carefully selected patients, a deliberate and temporary interruption of endocrine therapy to pursue pregnancy may be feasible without obvious short-term risk.
Longer therapy is not automatically better therapy. While extended endocrine therapy can meaningfully help some patients, the absolute benefit is often modest and variable, underscoring the need for individualized duration based on biology, tolerance, and patient goals.
The strongest safety concerns with post-breast-cancer hormone therapy come from older regimens, largely involving estrogen combined with synthetic progestogens. These agents are biologically distinct from micronized (bioidentical) progesterone, and we still lack recurrence-outcome data that directly address modern systemic biHRT in survivors, representing a critical evidence gap rather than a settled conclusion.
An integrative lens expands survivorship care beyond suppression alone, focusing on supporting estrogen metabolism, detoxification, redox balance, bone health, sleep, and quality of life to help reduce biologic stress and support long-term resilience.
Educational content only. This is not medical advice and does not replace individualized care of your oncology team.
For one-on-one consultations, visit drkseniamalarkey.com.